Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Company profile
Ticker
MNMD
Exchange
Website
CEO
Mr. Robert Barrow
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Sunlands Online Education Group
SEC CIK
Corporate docs
Subsidiaries
Mind Medicine, Inc. • MindMed Discover GmbH • MindMed Pty Ltd • Healthmode, Inc. ...
MNMD stock data
Analyst ratings and price targets
Latest filings (excl ownership)
424B3
Prospectus supplement
22 Oct 24
8-K
Entry into a Material Definitive Agreement
17 Oct 24
424B7
Prospectus with selling stockholder info
17 Oct 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
8-K
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
13 Aug 24
8-K
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
12 Aug 24
424B5
Prospectus supplement for primary offering
12 Aug 24
424B5
Prospectus supplement for primary offering
9 Aug 24
8-K
Entry into a Material Definitive Agreement
28 Jun 24
S-3ASR
Automatic shelf registration
28 Jun 24
Transcripts
MNMD
Earnings call transcript
2024 Q2
13 Aug 24
MNMD
Earnings call transcript
2024 Q1
8 May 24
MNMD
Earnings call transcript
2023 Q3
2 Nov 23
MNMD
Earnings call transcript
2023 Q2
3 Aug 23
MNMD
Earnings call transcript
2023 Q1
4 May 23
MNMD
Earnings call transcript
2022 Q4
9 Mar 23
MNMD
Earnings call transcript
2022 Q3
10 Nov 22
MNMD
Earnings call transcript
2022 Q2
12 Aug 22
MNMD
Earnings call transcript
2022 Q1
16 May 22
MNMD
Earnings call transcript
2021 Q4
28 Mar 22
Latest ownership filings
SC 13G
BlackRock, Inc.
22 Oct 24
144
Notice of proposed sale of securities
25 Sep 24
4
Carrie Liao
25 Sep 24
4
Robert Barrow
25 Sep 24
144
Notice of proposed sale of securities
25 Sep 24
4
Dan Karlin
25 Sep 24
4
Mark Sullivan
25 Sep 24
144
Notice of proposed sale of securities
25 Sep 24
4
DAVID W GRYSKA
26 Aug 24
4
Wernli Miri Halperin
22 Aug 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 243.13 mm | 243.13 mm | 243.13 mm | 243.13 mm | 243.13 mm | 243.13 mm |
Cash burn (monthly) | 3.07 mm | (no burn) | 8.15 mm | 7.54 mm | 6.66 mm | 6.15 mm |
Cash used (since last report) | 11.64 mm | n/a | 30.95 mm | 28.62 mm | 25.29 mm | 23.34 mm |
Cash remaining | 231.49 mm | n/a | 212.19 mm | 214.51 mm | 217.84 mm | 219.80 mm |
Runway (months of cash) | 75.5 | n/a | 26.0 | 28.4 | 32.7 | 35.8 |
Institutional ownership, Q2 2024
53.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 154 |
Opened positions | 51 |
Closed positions | 24 |
Increased positions | 37 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 297.55 bn |
Total shares | 43.38 mm |
Total puts | 452.70 k |
Total calls | 2.00 mm |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Commodore Capital | 7.15 mm | $51.52 bn |
Deep Track Capital | 6.10 mm | $44.01 bn |
BLK BlackRock | 5.38 mm | $38.82 bn |
Driehaus Capital Management | 2.54 mm | $18.30 bn |
Marshall Wace | 2.16 mm | $15.58 bn |
Octagon Capital Advisors | 2.15 mm | $15.52 bn |
CVI Investments | 1.97 mm | $0.00 |
BX Blackstone | 1.90 mm | $13.69 bn |
STT State Street | 1.81 mm | $13.01 bn |
Vanguard | 1.74 mm | $12.56 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Sep 24 | Dan Karlin | Common Shares | Sell | Dispose S | No | Yes | 5.98 | 6,871 | 41.09 k | 344,656 |
25 Sep 24 | Mark Sullivan | Common Shares | Sell | Dispose S | No | Yes | 5.98 | 4,430 | 26.49 k | 177,716 |
25 Sep 24 | Carrie Liao | Common Shares | Sell | Dispose S | No | Yes | 5.98 | 2,352 | 14.06 k | 99,543 |
25 Sep 24 | Robert Barrow | Common Shares | Sell | Dispose S | No | Yes | 5.98 | 19,771 | 118.23 k | 545,772 |
23 Aug 24 | Gryska David W | Common Shares | Buy | Acquire P | No | No | 5.98 | 3,500 | 20.93 k | 17,351 |
News
'DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands' - Marijuana Moment
23 Sep 24
Canaccord Genuity Maintains Buy on Mind Medicine, Lowers Price Target to $14
16 Sep 24
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
5 Sep 24
HC Wainwright & Co. Maintains Buy on Mind Medicine, Raises Price Target to $55
29 Aug 24
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
12 Aug 24
Press releases
MindMed Announces New Employee Inducement Grants
9 Sep 24
MindMed to Participate in September Investor Conferences
4 Sep 24
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
13 Aug 24
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
9 Aug 24
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
9 Aug 24